[Possibilities of pharmacological hepatopathy and correction of fat metabolism violations in diabetes mellitus type 1].
The purpose of the research has been the study of possibilities for the pharmacological correction of the morphological changes in liver and lipid metabolism disorders in experimental type 1 diabetes. Simvastatin, new compound from the group of antioxidants--3-hydroxipyridine derivate under the code HP-5, and also the combination of simvastatin and HP-5 have been used for the pharmacological correction in this research. It was revealed that the using of HP-5 and the combination of simvastatin and HP-5 attenuate the order of expression of diabetic hepatopathia as the result of the histological study and hinder from the development of dislipidemia in rates with type 1 diabetes which is more expressed in comparison with the monotherapy by simvastatin. These changes also are followed with the diminishing of the free radical lipid oxidation activity by the specific antioxidant effect of the investigated 3-hydroxipyridine derivate.
Semenova
E V
EV
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008099:Liver / Q000378:metabolism; D008297:Male; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D019821:Simvastatin / Q000494:pharmacology*
D000924:Anticholesteremic Agents; D000975:Antioxidants; D011725:Pyridines; C023500:3-hydroxypyridine; D019821:Simvastatin